510(k)

K020716: RAPID OPIATES TEST STRIP II, RAPID OPIATES TEST CARD II AND DOA MULTIPLE DRUG TEST CARDS (UP TO SIX TESTS)

FDA 510(k) · Rapid Diagnostics, Inc. · decided May 6, 2002

Key facts

510(k) number K020716
Device name RAPID OPIATES TEST STRIP II, RAPID OPIATES TEST CARD II AND DOA MULTIPLE DRUG TEST CARDS (UP TO SIX TESTS)
Applicant Rapid Diagnostics, Inc.
Product code DJG
Date received Mar 5, 2002
Decision date May 6, 2002
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Clinical Toxicology
Medical specialty Clinical Toxicology

At a glance

  • 1–9 MAUDE adverse event reports
  • None Recall events
  • None UDI device identifiers (GUDID)
  • None Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications